While the UK ties itself in knots over trans healthcare and the United States dismantles access state by state, Belgium has decided to do something quietly radical: fund gender-affirming surgery through its public health system. No ideological panic. No emergency parliamentary debate. Just a government deciding that trans people deserve healthcare, and paying for it.

That is what a healthcare system that trusts trans people actually looks like.

What Belgium has decided

According to the Times of Malta, the Belgian government is to cover the cost of gender-affirming surgery as part of its public health provision. The detail matters: this is not a loophole, not a pilot scheme, not a grudging exception buried in small print. It is a decision that trans people's healthcare needs are legitimate, and that the state has a role in meeting them, the same role it plays for every other citizen who needs medical care.

Gender-affirming surgery, like all surgical care, comes with risks, benefits, and individual clinical decisions to be made in partnership between the person and their clinical team. What Belgium has done is remove the financial barrier that stops those conversations from happening at all for too many people.

What is happening everywhere else

The contrast with the UK is sharp and painful. NHS waiting lists for gender services run to years, not months. The Cass Review, internationally discredited and built in part on research linked to gatekeeping networks, has been used to justify restricting care rather than improving it. Puberty blockers, medications with decades of safe use in paediatric medicine, are now banned for under-18s in England. Young trans people are waiting, suffering the physical and psychological consequences of that wait, while a political argument rages over whether they deserve care at all.

In the United States, the picture is darker still. Dozens of states have moved to ban or restrict gender-affirming care, particularly for young people. Clinics have closed. Families have relocated across state lines to access care their children need. The language used in legislatures and in media to describe this care, "experimental", "irreversible", "dangerous", is not clinical language; it is a political script designed to justify exclusion.

Delay is not a neutral position. Every month a trans person waits for care they need is a month of unnecessary distress, often a month of an unwanted puberty that cannot be undone, a month of depression, isolation, and the particular kind of exhaustion that comes from fighting for permission to exist. Belgium's decision recognises that. Most of Europe's healthcare systems do not, yet.

What good healthcare looks like

Belgium is not doing anything miraculous. It is doing something simple: treating trans healthcare as healthcare. The international standards that guide this field, most clearly the WPATH Standards of Care 8 and the Endocrine Society guidelines, are not fringe documents. They represent decades of clinical evidence and the considered positions of major medical organisations worldwide. Belgium is following them. The UK and the US, in their current directions, are not.

Good gender-affirming care is collaborative, informed, led by the person's own understanding of their needs, and supported by clinicians who are expert in this area. It is not uniquely experimental, uniquely risky, or uniquely in need of political supervision. Every area of medicine has ongoing research and evolving guidance. Gender care is no different, and it deserves no more suspicion than any other field.

What Belgium has done is signal clearly: trans people are people, their healthcare needs are real, and the public purse exists to meet real needs. That should not feel remarkable. The fact that it does tells us exactly how far too many countries still have to go.

If this is useful to you, please share it. Every share helps more people find accurate information about gender diversity.